Sodium-Glucose Cotransporter 2 Inhibitors for Patients with Prostate Cancer Undergoing Hormone Therapy

In this cohort study with a target trial emulation design, sodium-glucose cotransporter 2 (SGLT2) inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering.